Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial
Avatrombopag versus Placebo bei persistierender Chemotherapie-induzierter Thrombozytopenie bei GI-Karzinomen: Phase-II-Studie ACT-GI
Journal of Clinical Oncology · 01.11.2026 · 44 (31) · 3006-3014
DOI: 10.1200/jco-26-00568 ↗Auf einen Blick
In einer randomisierten, doppelblinden Studie erreichte Avatrombopag häufiger den primären Endpunkt als Placebo (70 % vs. 17 %).
Fragestellung
Wirkt Avatrombopag bei GI-Krebs mit persistierender chemotherapieinduzierter Thrombozytopenie besser als Placebo?
Methode
Multizentrische, randomisierte, doppelblinde US-Studie; 1:1 zu Avatrombopag oder Placebo bei persistierender CIT.
Ergebnisse
23 erhielten Avatrombopag, 24 Placebo. Primärer Endpunkt: 16/23 (70 %; 95 %-KI 47-87) vs. 4/24 (17 %; 95 %-KI 5-37), Z = 3,67; P < .001. Plättchenende: 157 (136-202) vs. 72 (68-134) × 10^9/L.
Schlussfolgerung der Autor:innen
Laut den Autor:innen war Avatrombopag in dieser randomisierten, placebokontrollierten Studie wirksam zur Behandlung persistierender CIT bei GI-Krebserkrankungen.
Kernaussagen
- Primärer Endpunkt: 70 % unter Avatrombopag vs. 17 % unter Placebo
- Medianer Plättchenwert am Zyklusende höher mit Avatrombopag
- Keine studienbedingten schweren UAW und keine Todesfälle berichtet
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.11.2026. Verfasst von Hanny Al-Samkari und 14 weiteren Autor:innen. Beteiligte Einrichtung: Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, MA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Gastrointestinal Neoplasms, Thiazoles, Thiophenes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE Chemotherapy-induced thrombocytopenia (CIT) is a challenging and common complication of cytotoxic chemotherapy in patients with GI cancers. There is no widely available approved treatment. Avatrombopag is a potent, second-generation oral thrombopoietin receptor agonist promising for CIT management. METHODS We conducted a multicenter, randomized, double-blind, investigator-initiated US trial of avatrombopag or placebo (1:1) in GI cancer patients with persistent CIT (platelets ≤85 × 10 9 /L on day 1 of a chemotherapy cycle despite adequate time to recover from the prior cycle). The primary end point was successful correction of CIT and prevention of recurrence (defined as recovery of platelets to ≥100 × 10 9 /L, no chemotherapy dose modification/delay, and prevention of CIT recurrence [platelets ≥100 × 109/L] at end of the on-study cycle). RESULTS The trial was closed to enrollment by the data and safety monitoring board at the planned interim analysis after meeting prespecified stopping criteria for efficacy. Sixteen of 23 patients (70% [95% CI, 47 to 87]) receiving avatrombopag achieved the primary end point versus 4/24 patients (17% [95% CI, 5 to 37]) receiving placebo ( Z = 3.67, P < .001). The median (IQR) platelet count at the end of the on-cycle treatment period was 157 (136-202) × 10 9 /L with avatrombopag versus 72 (68-134) × 10 9 /L with placebo. Adverse events (AEs) and serious AEs occurred in 78% and 17% of patients receiving avatrombopag and 46% and 0% of patients receiving placebo, respectively. No serious AEs were study drug-related. There were no treatment-related AEs leading to death or discontinuation of study drug. CONCLUSION In this randomized, placebo-controlled trial, avatrombopag was efficacious in the management of persistent CIT in patients with GI cancers. These findings are promising for a common, challenging oncologic complication that prevents delivery of full-dose, on-time, cancer-directed therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, MA.
- Harvard Medical School, Boston, MA.
- Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
- Fred Hutch Cancer Center, University of Washington, Seattle, WA.
- Dana-Farber Cancer Institute, Boston, MA.
- University of Miami Health System/Sylvester Comprehensive Cancer Center, Miami, FL.
ORCID-Profile: Hanny Al-Samkari, Julia H Keating, Adel Kardosh, Stacey A Cohen, Jonathan J Cohen, Gerald A Soff
Förderung
- NHLBI NIH HHS
Zitieren
APA
Al-Samkari, H., Shatzel, J. J., Panch, S. R., Keating, J. H., Walsh, E. P., Weekes, C. D., Kardosh, A., Cohen, S. A., Cohen, J. J., Hodges, P. G., Dhaver, S. E., Strojny, N., Donovan, C., Belibasakis, C., & Soff, G. A. (2026). Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial. Journal of Clinical Oncology, 44(31), 3006-3014. https://doi.org/10.1200/jco-26-00568
Vancouver
Al-Samkari H, Shatzel JJ, Panch SR, Keating JH, Walsh EP, Weekes CD, et al. Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial. Journal of Clinical Oncology. 2026;44(31):3006-3014. doi:10.1200/jco-26-00568
BibTeX
@article{AlSamkari2026,
author = {Al-Samkari, Hanny and Shatzel, Joseph J and Panch, Sandhya R and Keating, Julia H and Walsh, Elizabeth P and Weekes, Colin D and Kardosh, Adel and Cohen, Stacey A and Cohen, Jonathan J and Hodges, Pamela G and Dhaver, Shilton E and Strojny, Nina and Donovan, Carolyn and Belibasakis, Christos and Soff, Gerald A},
title = {Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {31},
pages = {3006--3014},
doi = {10.1200/jco-26-00568}
}
EUVIMED